CVAC: CureVac NV
About
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
Current Value
$2.591 Year Return
Current Value
$2.591 Year Return
Key Details
Market Cap
$574.22M
P/E Ratio
4.66
1Y Stock Return
-53.03%
1Y Revenue Growth
1202.27%
Dividend Yield
0.00%
Price to Book
0.7
Strategies that include CVAC
Stock's related to CVAC
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BNTX | 35.37% | $25.95B | +10.48% | 0.00% |
| CLFD | 33.18% | $427.99M | +11.09% | 0.00% |
| DMRC | 30.84% | $672.94M | -3.39% | 0.00% |
| PLRX | 30.37% | $781.97M | -7.75% | 0.00% |
| CDXS | 29.50% | $352.37M | +120.92% | 0.00% |
| PSTX | 29.36% | $264.13M | +3.83% | 0.00% |
| PGEN | 28.54% | $259.78M | -20.80% | 0.00% |
| IMUX | 27.85% | $99.99M | +5.71% | 0.00% |
| WIT | 27.77% | $35.48B | +42.95% | 0.17% |
| ARCT | 27.25% | $462.38M | -27.45% | 0.00% |
| ALT | 27.17% | $597.80M | +228.32% | 0.00% |
| JYNT | 27.12% | $173.36M | +25.08% | 0.00% |
| INN | 26.89% | $675.44M | 0.00% | 4.75% |
| CRSR | 26.71% | $755.93M | -42.49% | 0.00% |
| WOW | 26.50% | $434.90M | +14.25% | 0.00% |
| SAFE | 26.46% | $1.46B | +5.79% | 3.44% |
| LXP | 26.44% | $2.71B | +8.62% | 5.62% |
| STAG | 26.39% | $6.58B | +0.84% | 4.07% |
| UNFI | 26.29% | $1.41B | +54.62% | 0.00% |
| EBC | 26.19% | $3.98B | +53.01% | 2.37% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FAT | <0.01% | $91.75M | -8.47% | 10.57% |
| JELD | -0.03% | $887.66M | -33.44% | 0.00% |
| CNA | 0.05% | $13.33B | +23.85% | 3.57% |
| WHF | 0.06% | - | - | 14.69% |
| KMB | 0.07% | $45.70B | +12.03% | 3.52% |
| HDSN | 0.11% | $272.55M | -52.44% | 0.00% |
| KR | -0.13% | $42.38B | +33.68% | 2.07% |
| XBIO | 0.16% | $6.19M | +28.20% | 0.00% |
| GYRE | 0.16% | $1.10B | -27.06% | 0.00% |
| ADM | 0.19% | $25.43B | -28.44% | 3.78% |
| AFL | 0.19% | $62.07B | +35.55% | 1.78% |
| SRRK | 0.20% | $2.50B | +135.39% | 0.00% |
| CREG | -0.21% | $6.22M | -36.05% | 0.00% |
| NHTC | -0.21% | $64.47M | +3.99% | 13.82% |
| HIHO | 0.22% | $8.50M | -1.53% | 6.22% |
| TECX | 0.23% | $662.25M | +194.55% | 0.00% |
| GRPN | 0.24% | $365.86M | -8.73% | 0.00% |
| AIXI | -0.26% | $47.91M | -69.60% | 0.00% |
| EDR | 0.27% | $9.11B | +20.37% | 0.81% |
| HRTG | 0.30% | $377.42M | +62.70% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TEM | -14.09% | $8.26B | 0.00% | 0.00% |
| TCTM | -13.06% | $7.57M | -41.30% | 0.00% |
| CHD | -11.11% | $27.50B | +19.29% | 1.01% |
| AEE | -10.51% | $25.08B | +22.04% | 2.81% |
| EXC | -9.85% | $39.50B | +1.16% | 3.86% |
| CATX | -9.78% | $202.76M | +17.65% | 0.00% |
| PRT | -9.29% | $48.51M | -17.78% | 10.36% |
| CMG | -9.18% | $81.73B | +35.16% | 0.00% |
| AMED | -9.07% | $2.95B | -3.97% | 0.00% |
| CYCN | -8.65% | $3.85M | -33.95% | 0.00% |
| MSDL | -8.43% | $1.83B | +0.95% | 7.27% |
| RNR | -7.63% | $13.75B | +22.34% | 0.58% |
| FLUT | -7.43% | $47.48B | +61.35% | 0.00% |
| PGR | -7.37% | $154.33B | +62.01% | 0.44% |
| TEF | -7.21% | $24.97B | +7.52% | 7.35% |
| XGN | -7.17% | $69.14M | +151.28% | 0.00% |
| ADBE | -7.14% | $222.05B | -18.60% | 0.00% |
| AZO | -7.09% | $51.87B | +14.86% | 0.00% |
| PRGO | -7.03% | $3.69B | -11.07% | 4.04% |
| HUSA | -6.79% | $18.58M | -19.77% | 0.00% |
ETF's related to CVAC
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| JUCY | -0.05% | $325.31M | 0.6% |
| XBIL | -0.16% | $637.84M | 0.15% |
| IBHD | 0.38% | $325.68M | 0.35% |
| COMT | -0.43% | $842.63M | 0.48% |
| MINT | -0.66% | $11.62B | 0.35% |
| XONE | 0.71% | $550.61M | 0.03% |
| TPMN | -0.82% | $40.73M | 0.65% |
| DBMF | -0.82% | $1.02B | 0.85% |
| XHLF | -0.92% | $883.02M | 0.03% |
| GSG | 1.02% | $935.59M | 0.75% |
| FMF | 1.08% | $243.44M | 0.95% |
| GBIL | 1.14% | $5.64B | 0.12% |
| USCI | -1.17% | $185.92M | 1.07% |
| VRIG | 1.23% | $1.09B | 0.3% |
| HIGH | -1.51% | $301.36M | 0.51% |
| DBA | -1.75% | $768.98M | 0.93% |
| PDBC | 1.77% | $4.47B | 0.59% |
| CORN | 1.94% | $61.32M | 0.2% |
| DBC | 2.11% | $1.41B | 0.87% |
| WEAT | -2.12% | $123.26M | 0.28% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -21.88% | $379.51M | 1.43% |
| VIXY | -21.68% | $195.31M | 0.85% |
| USDU | -16.35% | $201.83M | 0.5% |
| UUP | -13.78% | $359.07M | 0.77% |
| KMLM | -13.60% | $348.59M | 0.9% |
| TAIL | -12.47% | $68.06M | 0.59% |
| BSJO | -8.29% | $452.72M | 0.43% |
| TBLL | -8.16% | $1.92B | 0.08% |
| CCOR | -6.56% | $108.59M | 1.18% |
| PHDG | -6.21% | $114.54M | 0.39% |
| CTA | -5.84% | $359.48M | 0.78% |
| EQLS | -5.45% | $8.88M | 1% |
| ULST | -5.30% | $535.66M | 0.2% |
| CLOI | -4.74% | $720.91M | 0.4% |
| BSCO | -4.03% | $2.31B | 0.1% |
| DBO | -3.52% | $218.38M | 0.77% |
| SGOV | -3.30% | $27.69B | 0.09% |
| DBE | -2.48% | $50.92M | 0.77% |
| WEAT | -2.12% | $123.26M | 0.28% |
| DBA | -1.75% | $768.98M | 0.93% |
News
Yahoo
Investors need to pay close attention to CureVac (CVAC) stock based on the movements in the options market lately.
Yahoo
We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where CureVac N.V. (NASDAQ:CVAC) stands against the other German stocks. In Germany, the economic growth is based on industry. According to Deutschland.de, Germany’s manufacturing industry contributed 26.6% to the country’s gross […]
Yahoo
How Novavax and others have restructured and trudged forward after their COVID-era high.
Yahoo
CureVac NV (CVAC) reports robust revenue growth and strategic advancements in oncology, despite ongoing litigation challenges.
SeekingAlpha
CureVac N.V. (NASDAQ:CVAC) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ETCompany ParticipantsSarah Fakih - Vice President of Corporate...
Yahoo
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed ...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.